Seres Therapeutics (MCRB) Work In Process (2023 - 2024)
Seres Therapeutics (MCRB) posted Work In Process of $48.1 million for Q2 2024, up 28.98% sequentially from $37.3 million in Q1 2024, and up 911.85% YoY from $4.8 million in Q3 2023.
Seres Therapeutics (MCRB) Work In Process (2023 - 2024) Analysis & Trends
Seres Therapeutics has reported Work In Process for 2 years, with the latest figure at $48.1 million in Q2 2024.
- Quarterly Work In Process rose 911.85% year-over-year to $48.1 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $48.1 million (up 911.85% YoY) and the FY2023 annual result came in at $25.2 million, changed N/A from the prior year.
- Work In Process grew to $48.1 million in Q2 2024 per MCRB's latest filing, from $37.3 million in the prior quarter.
- Over five years, Work In Process peaked at $48.1 million in Q2 2024 and troughed at $4.8 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - |
| 10 | Seres Therapeutics | 44.50 Mn | 44.50 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 48.06 Mn |
| Mar 31, 2024 | 37.27 Mn |
| Dec 31, 2023 | 25.22 Mn |
| Sep 30, 2023 | 14.99 Mn |
| Jun 30, 2023 | 4.75 Mn |